All VX-01 articles
-
News
Monoclonal antibody programme targets mucormycosis
Vitalex Biosciences has been awarded an SBIR Phase 2 grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health for VX-01, a monoclonal antibody (mAB) programme targeting the debilitating indication of the fungal disease, mucormycosis.